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In 2007, the Infectious Diseases 
Society of America (IDSA) and the 
Society for Healthcare Epidemiology 
of America jointly published the 
first guidelines for formation of 
antimicrobial stewardship programs 
(ASPs) intended to optimize patient 
care outcomes while minimizing 
antimicrobial resistance and drug 
toxicity.1 ASPs have proven beneficial 
in reducing the frequency and 
duration of target drug prescribing, 
occurrence of antiinfective–related 
infectious complications (eg, 
Clostridium difficile–associated 
disease) and health care costs with 
abstractBACKGROUND: Infectious Diseases Society of America guidelines recommend 
that key antimicrobial stewardship program (ASP) personnel include an 
infectious disease (ID) physician leader and dedicated ID-trained clinical 
pharmacist. Limited resources prompted development of an alternative 
model by using ID physicians and service-based clinical pharmacists at a 
pediatric hospital. The aim of this study was to analyze the effectiveness 
and impact of this alternative ASP model.
METHODS: The collaborative ASP model incorporated key strategies of 
education, antimicrobial restriction, day 3 audits, and practice guidelines. 
High-use and/or high-cost antimicrobial agents were chosen with audits 
targeting vancomycin, caspofungin, and meropenem. The electronic 
medical record was used to identify patients requiring day 3 audits and to 
communicate ASP recommendations. Segmented regression analyses were 
used to analyze quarterly antimicrobial agent prescription data for the 
institution and selected services over time.
RESULTS: Initiation of ASP and day 3 auditing was associated with blunting 
of a preexisting increasing trend for caspofungin drug starts and use and 
a significant downward trend for vancomycin drug starts (relative change 
–12%) and use (–25%), with the largest reduction in critical care areas. 
Although meropenem use was already low due to preexisting requirements 
for preauthorization, a decline in drug use (–31%, P = .021) and a 
nonsignificant decline in drug starts (–21%, P = .067) were noted. A 3-month 
review of acceptance of ASP recommendations found rates of 90%, 93%, and 
100% for vancomycin, caspofungin, and meropenem, respectively.
CONCLUSIONS: This nontraditional ASP model significantly reduced targeted 
drug usage demonstrating acceptance of integration of service-based 
clinical pharmacists and ID consultants.
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recent attention focusing on the 
role of ASP in quality improvement 
and patient safety.2 ASP programs 
in pediatric institutions have also 
favorably affected antimicrobial 
usage3–7 and recommendations 
for ASP development specific to 
pediatrics have been authored, 8, 9 
citing the importance of participation 
of an infectious disease (ID) 
physician and a trained clinical 
pharmacist.3, 4 However, limited 
availability of pediatric ID trained 
pharmacists and limited institutional 
resources may require modification 
of this classic ASP model.1, 8–10
In 2008, the Children’s Hospital of 
Pittsburgh of University of Pittsburgh 
Medical Center (UPMC) established 
an innovative collaborative model 
of shared ASP responsibilities by ID 
physicians and service-based clinical 
pharmacists under the direction of 
an ID physician leader and advisory 
committee. The program was 
developed from its onset to leverage 
the hospital’s electronic medical 
record (EMR) and data warehouse to 
facilitate ongoing evaluations of the 
ASP to inform potential additional 
interventions.
The aim of this study was to analyze 
the effectiveness of this alternative 
ASP model in improving the 
appropriateness of starts and overall 
use for 3 targeted antimicrobial 
agents.
METHODS
Setting
The Children’s Hospital of Pittsburgh 
of UPMC is a free-standing hospital 
with 315 beds, including 79 total 
ICU beds (36 PICU, 12 cardiac ICU, 
and 31 NICU). The hospital provides 
inpatient care for a wide range of 
clinical conditions from acute medical 
problems to the management of 
complex chronic diseases, including 
children with cancer and those 
undergoing solid organ and stem 
cell transplantation. Additionally, 
there are general surgery, neonatal 
surgery, cardiothoracic surgery, and 
orthopedic and trauma populations 
treated.
ASP Program Development.
In 2008, an ASP advisory committee 
representing clinical resource 
management, pharmacy services, 
ID, infection prevention, and 
medical informatics devised a 
unique model by using physician 
faculty and fellows and a team of 
service-based clinical pharmacists 
responsible for patient populations 
including critical care, oncology/
bone marrow transplantation, solid 
organ transplantation, and medical 
pediatrics. The physician director 
of the new ASP was provided 10% 
full-time equivalent (FTE) support 
but no other additional salary 
support was provided for the ASP. 
Preexisting antimicrobial restriction 
and preauthorization practices were 
continued. New activities included 
development of practice guidelines 
and implementation of prospective 
day 3 audits of targeted agents with 
education and feedback. Caspofungin, 
vancomycin, and meropenem were 
selected for auditing based on an 
assessment of usage patterns, cost 
impact, and/or potential for acquired 
drug resistance. ASP members 
collaborated with key physician 
services to develop guidelines 
emphasizing recommendations 
for initial as well as continued use 
at 72 hours of treatment of these 
antimicrobial agents. Guideline 
development for caspofungin began 
in January 2009 with implementation 
of day 3 auditing the same month. 
The efforts for vancomycin began in 
February 2009 with implementation 
of day 3 auditing in April 2010. 
Finally, efforts for meropenem began 
in August 2010 with initiation of day 
3 auditing in October 2010.
Data and Measures
Data collection was facilitated 
through use of the EMR (Cerner, 
Kansas City, MO); daily data 
warehouse reports were generated 
identifying patients requiring 
a day 3 audit. A customized 
ASP electronic note (eNote) 
template was constructed, 
permitting documentation of ASP 
recommendations in the EMR 
and also data collection for ASP 
program analysis. eNotes provided 
a recommendation to discontinue, 
continue, switch to an alternate 
antimicrobial, and/or consult ID 
with the option to include duration 
of treatment. Recommendations 
for dose adjustments were made 
by pharmacists in separate eNotes. 
Audits were completed by clinical 
pharmacists during the week 
and by ID physicians/fellows on 
weekends and holidays. Clinical 
status and potential indications for 
antimicrobial use were discussed 
as part of daily work rounds for 
those services with designated 
clinical pharmacists. An on-call 
ASP pharmacist performed day 3 
audits for all other patients. ASP 
recommendations were discussed 
with ID physicians as needed and 
communicated to the primary service 
both verbally and via eNote.
The data warehouse was further 
leveraged to evaluate ASP impact 
through the generation of quarterly 
reports assessing key endpoints 
including but not limited to drug 
starts (patients receiving drug 
per quarter/1000 patients per 
quarter) and drug use (days of 
therapy per quarter/1000 patient-
days per quarter). Preintervention 
antimicrobial use data were collected 
from the first quarter of 2008 
for caspofungin and vancomycin 
and from the first quarter of 
2009 for meropenem through 
the initiation of day 3 auditing 
for each targeted antimicrobial. 
Postintervention data were collected 
from the implementation of day 3 
auditing (first quarter of 2009 for 
caspofungin, second quarter of 2010 
for vancomycin, and fourth quarter 
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of 2010 for meropenem) through 
the third quarter of 2013 for all 
3 antimicrobial agents. Hospital-
wide and service-specific results 
for the targeted antimicrobial 
agents and other agents of interest 
(eg, piperacillin/tazobactam, 
ciprofloxacin) were reviewed on a 
quarterly basis to assess progress 
toward optimizing antimicrobial 
use. Unexpected increases in use of 
antimicrobial agents were discussed 
and educational interventions were 
implemented where appropriate with 
subsequent follow-up to determine 
the effectiveness of these additional 
efforts.
To assess acceptance of ASP 
recommendations, a chart review 
was conducted on all patients who 
had an ASP eNote written from 
October through December 2011. 
Acceptance of ASP recommendation 
was defined as following the 
recommendation within 24 hours 
of completion of eNote. Compliance 
was calculated as the percentage 
of ASP recommendations accepted 
versus number of eNotes written 
over the 3-month period for each 
antimicrobial.
Statistical Methods
Rates of drug starts and drug use 
were computed for each of the 
targeted antimicrobial agents 
on a quarterly basis. For each 
antimicrobial, 2-sample t tests were 
conducted to compare quarterly 
drug start and drug use rates before 
and after the ASP intervention. 
Segmented regression analyses11, 12 
were used to analyze the 
“interrupted time series” of quarterly 
antimicrobial prescriptions. Full 
segmented regression models 
included a preintervention intercept, 
a preintervention slope, a change 
in level after ASP (ie, a jump), and a 
change in slope post-ASP. Backward 
stepwise regression methods were 
used to create a parsimonious 
segmented regression models by 
eliminating parameters with P > 
.10. Data for individual services 
were examined as exploratory 
data analyses. Statistical analysis 
was carried out by using SAS 9.2 
(SAS Institute, Inc, Cary, NC) and P 
< .05 was considered statistically 
significant.
This work was approved by the 
Quality Improvement Committee of 
UPMC Health System.
RESULTS
Caspofungin was the first 
antimicrobial agent targeted by 
the ASP. This choice was driven 
in part by a marked increase in its 
use after a decision in 2008 by the 
hospital Pharmacy and Therapeutics 
Committee to place liposomal 
amphotericin B on our restricted 
antimicrobial list with the intent of 
redirecting empirical antifungal use 
toward caspofungin (Supplemental 
Table 1, Fig 1 A and B). The mean 
caspofungin start rate for the entire 
pre-ASP period (including data 
before and after caspofungin’s 
designation as recommended 
empirical antifungal agent) was 8.0 
patients per 1000 patients compared 
with 18.7 in the post-ASP period (P 
< .001), and the mean drug use rate 
was 14.0 and 29.3 patient-days per 
1000 patient-days in the pre and 
post-ASP periods, respectively (P = 
.003). After backward elimination of 
the “level change” variable (ie, the 
jump at time of ASP initiation), the 
parsimonious segmented regression 
model more clearly demonstrated a 
deceleration (ie, decreased slope) for 
drug starts and drug use after day 3 
auditing was initiated (P = .001 and 
P = .014, respectively) (Fig 1 A and 
B). In high-use physician services, 
increasing annual trends in usage 
were significantly blunted post-ASP 
(data not shown).
Vancomycin was the second targeted 
antimicrobial for day 3 auditing 
based on recognition of very high 
baseline use compared with other 
pediatric hospitals with highest 
institutional usage in critical care 
areas (unpublished data). Overall, 
the mean drug start rate was reduced 
from 137.7 patients per 1000 
patients pre-ASP period to 121.4 in 
the post-ASP period (P = .005), with 
mean drug use reduced from 138.2 
patient-days per 1000 patient-days 
before intervention to 104.2 post-ASP 
(P < .001). These changes represent 
a relative reduction of 12% for 
vancomycin drug starts and 25% for 
drug use. Parsimonious segmented 
regression analyses demonstrated 
constant drug start and drug use 
rates during the preintervention 
period compared with a significant 
downward trend for both measures 
after implementation of Day 3 
auditing (Supplemental Table 2, 
Fig 2 A and B). Exploratory analyses 
indicated observed reductions 
in usage occurred across all 
patient subpopulations (ie, 
postintervention slope <0), with 
greatest decline observed in solid 
organ transplant recipients receiving 
critical care.
Meropenem was the third drug 
selected for day 3 auditing based 
on concerns that overuse of this 
agent could lead to development 
of resistance in an antibiotic of 
last resort. As meropenem had 
required preauthorization before 
implementation of the ASP, its overall 
use was modest both before and after 
implementation of day 3 auditing. 
Despite this, the mean drug start rate 
dropped from 14.3 to 11.3 patients 
per 1000 patients for the pre-ASP 
and post-ASP periods, respectively 
(P = .067), and the mean drug 
use rate fell from 20.0 to 13.8 
patient-days per 1000 patient-
days for the pre- and post-ASP 
periods, respectively (P = .021), 
corresponding to a relative reduction 
of 21% for meropenem drug starts 
and 31% for drug use. The drop 
in association with initiation of 
day 3 auditing was confirmed by 
segmented regression modeling 
although no changes were observed 
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in drug start and use rates comparing 
the pre-ASP period and post-ASP time 
periods (Fig 3 A and B, Supplemental 
Table 3). Meropenem was most 
frequently prescribed in the PICU 
for abdominal transplant candidates 
and recipients; the reduction in 
meropenem use after the initiation 
of the ASP in this subpopulation was 
consistent with the findings in the 
overall population. Meropenem use 
in other patient populations was 
too limited to allow for meaningful 
subgroup analysis.
To assess whether potential 
changes in patient characteristics 
might explain observed changes 
in antimicrobial use over time, a 
comparison of the average number 
of patients per quarter and patient 
days per quarter before and after 
the introduction of our ASP was 
performed. The average number of 
total patients per quarter and total 
patient-days per quarter were similar 
before and after the intervention 
(3282 vs 3410 for total patients 
per quarter and 21 502 vs 22 412 
for total patient-days per quarter, 
respectively). Among the higher-risk 
population, the average number 
patients per quarter and patient-
days per quarter were greater after 
implementation of day 3 auditing 
for ICU (576 vs 638 for total patients 
per quarter and 3512 vs 3828 for 
total patient-days per quarter, 
respectively), NICU (168 vs 205 for 
total patients per quarter and 1933 
vs 3201 for total patient-days per 
quarter, respectively), and oncology/
bone marrow transplantation 
e4
 FIGURE 1 A AND B, 
Caspofungin prescription data were collected from 2008 Quarter 1 through 2013 Quarter 3, and the Caspofungin ASP intervention was initiated in 2009 
Quarter 1 (red dashed line). The y-axis for Fig 1A provides caspofungin cases per 1000 total cases, whereas for Fig 1B it provides caspofungin days 
per 1000 total patient-days. The x-axis provides the quarter/year of observation. The observed quarterly data (blue line with diamonds) and the fi tted 
parsimonious segmented regression model (red solid line) for the drug start rates are shown in the top panel and the drug use rates are shown in the 
bottom panel.
 FIGURE 2 A AND B, 
Vancomycin prescription data were collected from 2008 Quarter 1 through 2013 Quarter 3, and the Vancomycin ASP intervention was initiated in 2009 
Quarter 2 (red dashed line). The y-axis for Fig 2A provides vancomycin cases per 1000 total cases, whereas for Fig 2B it provides vancomycin days per 1000 
total patient-days. The x-axis provides the quarter/year of observation. The observed quarterly data (blue line with diamonds) and the fi tted parsimonious 
segmented regression model (red solid line) for the drug start rates are shown in the top panel and the drug use rate are shown in the bottom panel.
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patients were decreased in our 
abdominal transplant population 
(112 vs 94 for total patients per 
quarter and 1258 vs 957 for 
total patient-days per quarter, 
respectively).
Results of the audit of compliance 
with ASP recommendations 
demonstrated an overall acceptance 
rate of 90%, 93%, and 100% for 
vancomycin, caspofungin, and 
meropenem, respectively. The 
decline in numbers of patients 
initially receiving vancomycin and 
overall drug use is more impressive 
when considering that these 
results were accompanied by a 
progressive decrease in the number 
of vancomycin ASP notes over time 
(Fig 4).
DISCUSSION
Initiation of our alternative model 
ASP was associated with a decline 
in drug starts and overall drug use 
for the 3 targeted antimicrobial 
agents evaluated in this study. Our 
analyses demonstrated blunting of 
a preexisting increasing trend for 
caspofungin drug starts, as well as 
use, and a significant downward 
trend for vancomycin drug starts 
(relative change –12%) and use 
(–25%), with the largest reduction 
in critical care areas. Although 
meropenem use was already low 
due to preexisting requirements 
for preauthorization, a decline in 
drug use (–31%, P = .021) and a 
nonsignificant decline in drug starts 
(–21%, P = .067) were noted. Our 
analysis further demonstrated 
levels of acceptance of ASP 
recommendations of 90%, 93%, and 
100% for vancomycin, caspofungin, 
and meropenem, respectively. Taken 
together, the impact on antimicrobial 
starts and overall use along with 
the high level of acceptance of 
recommendations strongly support 
the effectiveness of this alternative 
model of ASP.
The use of ASPs is an increasingly 
important strategy to optimize use 
of antimicrobial agents. A recent 
survey of free-standing children’s 
hospitals revealed that 38% had 
formal ASP, whereas an additional 
36% were actively implementing 
programs.13 Common antimicrobial 
agents monitored included 
vancomycin, linezolid, daptomycin, 
fluoroquinolones, and carbapenems. 
Prospective audit and feedback, 
formulary restriction, and clinical 
guidelines were commonly cited 
strategies (87%).13 In 2008, an ASP 
e5
 FIGURE 3 A AND B, 
Meropenem prescription data were collected from 2009 Quarter 1 through 2013 Quarter 3, and the Meropenem ASP intervention was initiated in 2010 
Quarter 4 (red dashed line). The y-axis for Fig 3A provides meropenem cases per 1000 total cases, whereas for Fig 3B it provides meropenem days per 1000 
total patient-days. The x-axis provides the quarter/year of observation. The observed quarterly data (blue line with diamonds) and the fi tted parsimonious 
segmented regression model (red solid line) for the drug start rates are shown in the top panel and the drug use rates are shown in the bottom panel.
 FIGURE 4
The number of ASP notes written over time.
 at Univ of NC at Chapel Hill on August 15, 2019www.aappublications.org/newsDownloaded from 
 NGUYEN-HA et al 
was constructed at this pediatric 
hospital by using key strategies 
recommended by the IDSA1 (eg, 
education, drug restriction, and 
auditing). However, the institution 
chose a nontraditional model 
to operationalize the program, 
integrating ASP activities into the 
daily function of service-based 
clinical pharmacists and of ID 
physicians during weekends and 
holidays. Multiple ASP strategies, 
including development of consensus 
guidelines for drug use with key 
physician stakeholders, requirement 
for approval before initiation of drug 
use for targeted antimicrobial agents, 
and ASP auditing on day 3, as well as 
ongoing education were used.1, 11 The 
hospital’s EMR and data warehouse 
were leveraged to identify patients 
requiring day 3 auditing, document 
ASP recommendations, and track and 
analyze trends in drug use over time.
An important primary endpoint 
for assessing the success of an ASP, 
regardless of model, is its impact 
on antimicrobial use. Although 
our ASP has worked to educate 
prescribing physicians about the use 
of antimicrobial agents in general, 
our outcome analyses focused on the 
3 agents selected for day 3 auditing. 
The primary variables analyzed were 
drug starts and use (overall and 
for individual clinical services) for 
each targeted antimicrobial agent. 
Although our analyses suggest that 
implementation of day 3 auditing 
had a positive significant effect on all 
3 agents, the impact on vancomycin 
was most dramatic. A stable but 
very high rate of both vancomycin 
starts and use were noted for the 2 
years before implementation of day 
3 auditing. After the intervention, a 
significant and ongoing steep drop in 
both the number of patients started 
on vancomycin and its overall use 
has been documented for the whole 
hospital and for most of our high-
risk clinical services. The observed 
reductions in vancomycin starts and 
use are similar to those reported by 
Di Pentima and Chan, 3 describing 
a 33% decline in vancomycin use 
as measured in doses administered 
per 1000 patient-days per year in 
a pediatric hospital after 3 years 
of auditing by using a “traditional” 
model of ASP. By comparison, we 
demonstrated an ∼25% decline in the 
use of vancomycin as measured by 
drug days per 1000 patient-days in a 
similar time period. Additionally, we 
have anecdotally observed that our 
physician services are more readily 
discontinuing vancomycin therapy 
before day 3 audits, suggesting that 
physicians are deescalating therapy 
when appropriate as part of daily 
patient care, independent of a formal 
ASP eNote.
The incorporation of daily ASP 
activities into the work of the 
service-based clinical pharmacists 
who participate in daily rounds 
takes advantage of established 
collaborative relationships between 
pharmacists and physician services, 
connecting ASP activities with 
pharmacist responsibility allowing 
for more informed prospective 
patient care reviews and assessment. 
We believe that use of service-based 
pharmacists for execution of our 
ASP allows for a more effective 
integration of antimicrobial 
stewardship into clinical decision-
making and may be a major reason 
for observed high rates of compliance 
with ASP recommendations 
and reduction in use of targeted 
antimicrobial agents. As many 
children’s hospitals also include 
service-based pharmacists as part of 
clinical care teams, the model of ASP 
implemented at our institution may 
be an effective alternative approach 
for these facilities.
Potential negative issues could be 
associated with the implementation 
of this alternative ASP compared 
with the traditional model that uses 1 
dedicated physician and pharmacist. 
The current model requires that 
all service-based pharmacists 
and ID physicians be educated 
and trained in the conduct of the 
ASP, which might be challenging if 
turnover were frequent or if large 
numbers of individuals need to 
be reeducated due to infrequent 
service obligation. Another 
concern was possible hesitation by 
service-based pharmacists to make 
recommendations that diverge from 
the therapeutic plan of providers 
worked with on a daily basis. This 
concern was not borne out, as noted 
by the decline in use of targeted 
antimicrobial agents highlighted 
in this article. Finally, the lack of 
additional FTE support could limit 
the scope of ASP efforts compared 
with programs using dedicated 
personnel.
In contrast to the current ASP model, 
use of dedicated ASP pharmacists is 
common in both adult and pediatric 
stewardship programs. Newland 
et al13 reported that 13 of 16 free-
standing pediatric hospitals with 
ASPs had dedicated pharmacist 
FTEs (median 0.5, range 0.1–1.5 
FTE). The described model provides 
an effective alternative that may 
be particularly attractive when 
resources to support additional 
clinical pharmacists and physicians 
are limited. Other institutions also 
have adopted models unique to their 
culture and resources with success. 
DiazGranados and Abd14 reported 
a similar model of multiple clinical 
pharmacists’ participation in ASP 
activities achieving significant cost-
savings. Bartlett and Siola15 also 
reported successful cost-containment 
initiatives with a 74% acceptance 
of ASP recommendations when 
multiple clinical pharmacists without 
specialized ID training participated. 
Their model differs from our model 
in that one payroll neutral ASP 
position was created with coverage 
of their ASP rotating among all 
dispensing and clinical pharmacists 
on a weekly basis.
This program leveraged the 
capabilities of the EMR and 
associated data warehouse for 
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identification of patients requiring 
day 3 auditing and for documentation 
and communication of ASP 
recommendations to clinical teams. 
In addition, use of a data warehouse 
empowers the ASP program through 
the ability to generate real-time data 
regarding antimicrobial use through 
quarterly reports of patient numbers, 
usage, and duration of treatment 
of both hospital-wide and service-
specific populations of interest. The 
availability of these reports allowed 
for the equivalent of ongoing PDSA 
(Plan, Do, Study, Act) cycles16 to 
review our experience and further 
enhance the impact of the ASP.
The current study suffers from 
several potential limitations. Because 
the EMR and data warehouse were 
used as the basis for analyses of 
the program’s effectiveness, we 
were not able to provide disease-
specific data on the impact of 
our intervention or correlate the 
impact of the ASP on length of stay, 
mortality, and so forth. However, 
current recommendations by the 
IDSA support assessment of whether 
ASPs result in desired changes in 
antimicrobial use. We believe that 
measurement of drug starts and 
usage accomplish this goal. Similarly, 
we do not have complete details 
of patient clinical characteristics 
before and after implementation of 
our ASP. Accordingly, some of the 
observed changes in antimicrobial 
use could be due to differences in 
patient characteristics in these 2 
time periods. However, the analyses 
of total patients per quarter and 
patient-days per quarter and in 
particular the comparison of these 
data for higher-risk populations (eg, 
patients in the ICU, children with 
cancer) suggests more children in 
the postintervention period belonged 
to higher-risk groups suggesting 
that observed changes would not 
be due to a shift to lower-acuity 
patients who would require less 
antimicrobial therapy. An additional 
limitation to this work was the 
ability to look at quarterly drug 
prescription information only from 
2008 onward, which prevented us 
from meeting the typical expectation 
of 12 observations before and after 
an intervention. Nonetheless, the 
magnitude of the observed changes 
after the intervention (especially for 
vancomycin) support the validity of 
the current analyses.
CONCLUSIONS
The implementation of a unique 
collaborative ASP model by using 
expertise of service-based clinical 
pharmacists and ID physician 
members successfully reduces 
drug usage of targeted drugs 
and provides an alternative to 
the “traditional” ASP model as 
originally envisioned. This approach 
to antimicrobial stewardship 
represents a viable alternative to 
current recommendations for the 
implementation of stewardship 
programs.
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